NepalTuberculosis profile
Population  2018 28 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 42 (37–48) 151 (133–170)
HIV-positive TB incidence 0.38 (0.32–0.45) 1.4 (1.1–1.6)
MDR/RR-TB incidenceºº 1.4 (0.77–2.3) 5 (2.8–8)
HIV-negative TB mortality 5.4 (3.8–7.3) 19 (13–26)
HIV-positive TB mortality 0.093 (0.071–0.12) 0.33 (0.25–0.42)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 2.2% (1.1–3.6)
Previously treated cases 15% (9.6–22)
TB case notifications, 2018  
Total new and relapse 31 855
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 69%
          - % pulmonary 71%
          - % bacteriologically confirmedººº 80%
          - % children aged 0-14 years 5%
          - % women 34%
          - % men 61%
Total cases notified 32 474
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 75% (67–85)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 13% (9–18)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 200 <1%
          - on antiretroviral therapy 190 95%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 50%
          - Previously treated cases 56%
Laboratory-confirmed cases* MDR/RR-TB: 669, XDR-TB: 29
Patients started on treatment* ** MDR/RR-TB: 400, XDR-TB: 20
MDR/RR-TB cases tested for resistance to second-line drugs 412
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 91% 31 219
Previously treated cases, excluding relapse, registered in 2017 81% 425
HIV-positive TB cases registered in 2017 83% 121
MDR/RR-TB cases started on second-line treatment in 2016 68% 348
XDR-TB cases started on second-line treatment in 2016 61% 18
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
9.4% (8.6–10)
TB financing, 2019  
National TB budget (US$ millions) 20
Funding source: 39% domestic, 38% international, 24% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2020-04-09 Data: www.who.int/tb/data